A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma

Biochemistry, Genetics and Molecular Biology

• Immune Checkpoint Inhibitor 100%
• DNA Damage 33%
• Gene Expression 33%
• T Cell 33%
• Myeloid 33%
• Cell Cycle 33%
• CD8 33%
• Macrophage 33%
• Dendritic Cell 33%
• RNA Splicing 33%
• Immunogenicity 33%
• Chromatin Remodeling 33%
• Mann-Whitney U Test 33%
• Alpha Thalassemia/Mental Retardation X-Linked 33%
• PD-L1 33%
• SF3B1 33%
• Immune Checkpoints 33%

Keyphrases

• Tumor Subtype 100%
• Metastatic Melanoma 100%
• Vulvovaginal Melanoma 100%
• Melanoma Patients 16%
• Melanocytic Tumor 16%
• Molecular Profile 16%
• Immune Profile 16%
• Multiple Comparisons 8%
• Molecular Analysis 8%
• DNA Damage 8%
• Statistical Significance 8%
• Gene Expression 8%
• New Therapeutic Strategies 8%
• Macrophages 8%
• Survival Data 8%
• CD8+ T Cells 8%
• Chi-square 8%
• Immune Checkpoint Inhibitors 8%
• Programmed Death-ligand 1 (PD-L1) 8%
• Immunogenicity 8%
• RNA Splicing 8%
• Chromatin Remodeling 8%
• Molecular Profiling 8%
• Treatment Information 8%
• Wilcoxon Rank Sum Test 8%
• Myeloid Dendritic Cells 8%
• KIT mutation 8%
• Cell Fraction 8%
• Immune Checkpoint Inhibitor Therapy 8%
• ATRX mutation 8%
• Immune Checkpoint Genes 8%
• Immune Profiling 8%
• Insurance Claims Data 8%
• Immune Checkpoint Inhibitor Treatment 8%
• SF3B1 mutation 8%
• Inhibitor Agent 8%

Medicine and Dentistry

• Neoplasm 100%
• Melanoma Skin Cancer 100%
• Melanoma 100%
• Immune Checkpoint Inhibitor 25%
• Tumor 16%
• DNA Damage 8%
• Macrophage 8%
• Cell Cycle 8%
• Gene Expression 8%
• Cytotoxic T-Cell 8%
• Programmed Death-Ligand 1 8%
• Rank Sum Test 8%
• Immunogenicity 8%
• Chromatin Remodeling 8%
• Myeloid Dendritic Cell 8%
• RNA Splicing 8%